Journal Watch · Blood · 2026

The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.

IGHV4-34 is a paradigm of the plasticity of B cells, of interaction with potential autoantigens, and of their subversion in tumors.

Stevenson FK, Stamatopoulos KBlood3 min readPharma relevance 40/100

DOI: 10.1182/blood.2025032357PMID: 41557911Study type: research study

TL;DR

IGHV4-34 is a paradigm of the plasticity of B cells, of interaction with potential autoantigens, and of their subversion in tumors.

Key findings

  • Structurally, both the interaction of the 9G4 MoAb and the ability of the IGHV4-34-encoded protein to bind to N-acetyl lactosamine-containing sequences, rely on hydrophobic amino acids located in 2 positions of the looped FR1 sequence of the variable domain.
  • This offers a focused site for blockade.
  • IGHV4-34 is a paradigm of the plasticity of B cells, of interaction with potential autoantigens, and of their subversion in tumors.

What they did

IGHV4-34+ B cells secrete immunoglobulin M (IgM) in various hematologic conditions, including the mandatory association with cold agglutinins, and the transient expansions of usage (not always overt agglutination) are observed in Epstein-Barr virus, cytomegalovirus, Mycoplasma pneumoniae, and other infections. Perhaps connected to that, certain autoimmune conditions, such as systemic lupus erythematosus, show increases in IGHV4-34 expression, which correlate with disease flares. Intriguingly, there is preferential usage of IGHV4-34 in a wide range of lymphomas and in the IgG variant of chronic lymphocytic leukemia, suggestive of an autoantigenic drive.

Full abstract (original)

Background: <h4>Abstract</h4>B cells expressing the IGHV4-34 gene sit at the center of a web of B-cell functions, ranging from natural antibodies induced by infection to autoimmunity and tumors. Tracking via the 9G4 monoclonal antibody (MoAb) specifically directed against the unique flag sequences in the first framework region 1 (FR1) of IGHV4-34, allows insight into the evolving nature and multiple functions of B cells expressing a single IGHV gene. IGHV4-34+ B cells are found early in development, and the expansion indicative of a superantigenic drive occurs with increasing age.

What they did: IGHV4-34+ B cells secrete immunoglobulin M (IgM) in various hematologic conditions, including the mandatory association with cold agglutinins, and the transient expansions of usage (not always overt agglutination) are observed in Epstein-Barr virus, cytomegalovirus, Mycoplasma pneumoniae, and other infections. Perhaps connected to that, certain autoimmune conditions, such as systemic lupus erythematosus, show increases in IGHV4-34 expression, which correlate with disease flares. Intriguingly, there is preferential usage of IGHV4-34 in a wide range of lymphomas and in the IgG variant of chronic lymphocytic leukemia, suggestive of an autoantigenic drive.

Results & conclusions: Structurally, both the interaction of the 9G4 MoAb and the ability of the IGHV4-34-encoded protein to bind to N-acetyl lactosamine-containing sequences, rely on hydrophobic amino acids located in 2 positions of the looped FR1 sequence of the variable domain. This offers a focused site for blockade. IGHV4-34 is a paradigm of the plasticity of B cells, of interaction with potential autoantigens, and of their subversion in tumors.

Abstract © the authors / Blood (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1182/blood.2025032357 · PubMed 41557911.

Why it matters for pharma & biotech

  • Directly relevant to teams in antibody / ADC therapeutics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: antibody / ADC therapeutics

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Blood study find?

IGHV4-34 is a paradigm of the plasticity of B cells, of interaction with potential autoantigens, and of their subversion in tumors.

What type of study is this?

It is a research study, published in Blood in 2026. IGHV4-34+ B cells secrete immunoglobulin M (IgM) in various hematologic conditions, including the mandatory association with cold agglutinins, and the transient expansions of usage (not always overt agglutination) are observed in Epstein-Barr virus, cytomegalovirus, Mycoplasma pneumoniae, and other infections.

Where can I read the original paper?

The original is at the publisher via DOI 10.1182/blood.2025032357. PubMed ID: 41557911. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Stevenson FK, Stamatopoulos K. The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.. Blood (2026). DOI: 10.1182/blood.2025032357.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-singularity-of-ighv4-34-links-infection-autoimmunity-and-b-cell-tumo-032357/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides